Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via Weight Watchers Med+ from $149 per month ...

Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.

For the past three years, our friends and colleagues have been shrinking all around us. You probably know someone who is 'on ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

Boots has launched an in-store service for weight loss drugs aimed at people 'popping out on their lunch break.' ...

The pharmacy chain has launched the service as a trial initially across 17 stores offering treatments such as Mounjaro and Wegovy on the high street for the first time.

BOOTS is now offering customers an in-store fat jab service allowing people to pop in and buy jabs in their lunch breaks. The pharmacy chain has launched the service as a trial initially across 17 ...

With this in mind, I bit the bullet and made the financial decision to give Mounjaro a go. Being the height I am (short) and ...

The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill.